Therapeutic Potential of an Anti-CCR9 MAb Evidenced in Xenografts of Human CCR9 Tumors

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Aug 15

PMID 35967322

Authors

Silvia Santamaria

Marisa Delgado

Marta Botas

Eva Castellano

Isabel Corraliza-Gorjon

Paloma Lafuente

Cecilia Munoz-Calleja

Maria L Toribio

Leonor Kremer

Jose A Garcia-Sanz

Affiliations

Soon will be listed here.

Abstract

Relapsed or refractory T acute lymphoblastic leukemia (T-ALL) still carries poor prognosis. Aiming to improve outcomes, the therapeutic potential of an anti-CCR9 monoclonal antibody (mAb 92R), targeting the human chemokine-receptor CCR9 is analyzed on orthotopic xenotransplants. 92R mAb treatment of mice carrying human CCR9 T-ALL cell lines or primary T cell leukemias inhibits tumor growth and increases survival. The therapeutic effects of 92R are specific and synergize with chemotherapeutic agents increasing survival. Furthermore, 92R decreases size of non-hematopoietic tumors with a forced CCR9 expression and of solid tumors generated by the pancreatic adenocarcinoma cell line AsPC-1. In addition, a humanized version of 92R mAb (Srb1) is also able to inhibit growth of CCR9 T-ALL tumor cells , increasing survival 2.66-fold. Finally, 92R mAb prevents liver accumulation of infiltrates and reduces tumor cell numbers in already formed infiltrates. Thus, the humanized version of 92R mAb (Srb1), displays therapeutic potential for CCR9 tumor treatment and might represent one of the first therapeutic antibodies for precision medicine on T-ALL patients.

Citing Articles

Integrated whole-exome and bulk transcriptome sequencing delineates the dynamic evolution from preneoplasia to invasive lung adenocarcinoma featured with ground-glass nodules.

Zhou D, Li Y, Liu Q, Deng X, Chen L, Li M Cancer Med. 2024; 13(11):e7383.

PMID: 38864483 PMC: 11167609. DOI: 10.1002/cam4.7383.

Therapeutic Monoclonal Antibodies against Cancer: Present and Future.

Delgado M, Garcia-Sanz J Cells. 2023; 12(24).

PMID: 38132155 PMC: 10741644. DOI: 10.3390/cells12242837.

Notch Partners in the Long Journey of T-ALL Pathogenesis.

Toribio M, Gonzalez-Garcia S Int J Mol Sci. 2023; 24(2).

PMID: 36674902 PMC: 9866461. DOI: 10.3390/ijms24021383.

References

Chamorro S, Vela M, Franco-Villanueva A, Carramolino L, Gutierrez J, Gomez L . Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs. 2014; 6(4):1000-12. PMC: 4171004. DOI: 10.4161/mabs.29063. View

Zhang Z, Sun T, Chen Y, Gong S, Sun X, Zou F . CCL25/CCR9 Signal Promotes Migration and Invasion in Hepatocellular and Breast Cancer Cell Lines. DNA Cell Biol. 2016; 35(7):348-57. DOI: 10.1089/dna.2015.3104. View

Johnson E, Singh R, Johnson-Holiday C, Grizzle W, Partridge E, Lillard Jr J . CCR9 interactions support ovarian cancer cell survival and resistance to cisplatin-induced apoptosis in a PI3K-dependent and FAK-independent fashion. J Ovarian Res. 2010; 3:15. PMC: 2914045. DOI: 10.1186/1757-2215-3-15. View

Carramolino L, Zaballos A, Kremer L, Villares R, MARTIN P, Ardavin C . Expression of CCR9 beta-chemokine receptor is modulated in thymocyte differentiation and is selectively maintained in CD8(+) T cells from secondary lymphoid organs. Blood. 2001; 97(4):850-7. DOI: 10.1182/blood.v97.4.850. View

Tu Z, Xiao R, Xiong J, Tembo K, Deng X, Xiong M . CCR9 in cancer: oncogenic role and therapeutic targeting. J Hematol Oncol. 2016; 9:10. PMC: 4754913. DOI: 10.1186/s13045-016-0236-7. View

Cyster J . Lymphoid organ development and cell migration. Immunol Rev. 2003; 195:5-14. DOI: 10.1034/j.1600-065x.2003.00075.x. View

Youn B, Kim C, Smith F, Broxmeyer H . TECK, an efficacious chemoattractant for human thymocytes, uses GPR-9-6/CCR9 as a specific receptor. Blood. 1999; 94(7):2533-6. View

Zaballos A, Gutierrez J, Varona R, Ardavin C, Marquez G . Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol. 1999; 162(10):5671-5. View

Zabel B, Agace W, Campbell J, Heath H, Parent D, Roberts A . Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med. 1999; 190(9):1241-56. PMC: 2195678. DOI: 10.1084/jem.190.9.1241. View

10.

Maciocia P, Wawrzyniecka P, Maciocia N, Burley A, Karpanasamy T, Devereaux S . Anti-CCR9 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia. Blood. 2022; 140(1):25-37. DOI: 10.1182/blood.2021013648. View

11.

Kunkel E, Campbell J, Haraldsen G, Pan J, Boisvert J, Roberts A . Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med. 2000; 192(5):761-8. PMC: 2193265. DOI: 10.1084/jem.192.5.761. View

12.

Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, Pabst O . CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc Natl Acad Sci U S A. 2007; 104(15):6347-52. PMC: 1851094. DOI: 10.1073/pnas.0609180104. View

13.

Heinrich E, Arrington A, Ko M, Luu C, Lee W, Lu J . Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. Cancer Microenviron. 2013; 6(3):241-5. PMC: 3855378. DOI: 10.1007/s12307-013-0130-6. View

14.

Amersi F, Terando A, Goto Y, Scolyer R, Thompson J, Tran A . Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res. 2008; 14(3):638-45. PMC: 2760931. DOI: 10.1158/1078-0432.CCR-07-2025. View

15.

Qiuping Z, Qun L, Chunsong H, Xiaolian Z, Baojun H, Mingzhen Y . Selectively increased expression and functions of chemokine receptor CCR9 on CD4+ T cells from patients with T-cell lineage acute lymphocytic leukemia. Cancer Res. 2003; 63(19):6469-77. View

16.

Qiuping Z, Jei X, Youxin J, Wei J, Chun L, Jin W . CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation. Cancer Res. 2004; 64(20):7579-87. DOI: 10.1158/0008-5472.CAN-04-0641. View

17.

van den Oord J . The CCR9-CCL25 axis mediates melanoma metastasis to the small intestine. Nat Clin Pract Oncol. 2008; 5(8):440-1. DOI: 10.1038/ncponc1174. View

18.

Vicari A, Figueroa D, Hedrick J, Foster J, Singh K, Menon S . TECK: a novel CC chemokine specifically expressed by thymic dendritic cells and potentially involved in T cell development. Immunity. 1997; 7(2):291-301. DOI: 10.1016/s1074-7613(00)80531-2. View

19.

Sharma P, Singh R, Novakovic K, Eaton J, Grizzle W, Singh S . CCR9 mediates PI3K/AKT-dependent antiapoptotic signals in prostate cancer cells and inhibition of CCR9-CCL25 interaction enhances the cytotoxic effects of etoposide. Int J Cancer. 2010; 127(9):2020-30. DOI: 10.1002/ijc.25219. View

20.

Ben-Baruch A . Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis. 2007; 25(4):345-56. DOI: 10.1007/s10585-007-9097-3. View